Nexvet Appoints New Vice-President of Operations and General Counsel

Nexvet Appoints New Vice-President of Operations and General Counsel


(AUGUST 12, 2013) Melbourne, Australia. Australian veterinary biologic drug developer Nexvet Biopharma (Nexvet) has appointed Geraldine Farrell as its Vice-President of Operations and General Counsel.

Most recently holding the position of Special Counsel at Griffith Hack IP Lawyers in Melbourne, Ms Farrell specialises in Intellectual Property (IP) and technology law, and has almost two decades of experience across biotechnology, pharmaceuticals, mining, clean technology and the software/ICT sectors.

Alongside her legal role at Griffith Hack, Ms Farrell has been a Swinburne University Council Member since March 2009 and is a Director of Swinburne Ventures, a wholly owned subsidiary of Swinburne University and the company responsible for holding and commercialising the university's intellectual property. She is also a current member of the Red Cross Blood Service's ethics committee and was formerly a Director of AusBiotech, Australia's biotechnology industry association.

Nexvet CEO Mark Heffernan said Ms Farrell would perform a crucial role for the company.

"Not only does Geraldine bring a sharp legal mind to Nexvet in the areas of IP, technology and commercialisation, she has significant biotech experience through her time as a Director at AusBiotech and having acted for several of Australia's biotechnology companies," Dr Heffernan said.

"Geraldine joins Nexvet at an important time for the company as we rapidly develop our unique portfolio of animal drugs for the treatment of canine, feline and equine diseases, including osteoarthritis, inflammatory diseases and cancer. "To appoint someone of Ms Farrell's calibre is a real boon for Nexvet and further strengthens our management team as we advance our product portfolio clinically and commercially and explore other opportunities for growth."

Nexvet is using its proprietary technology PETisation™ platform, which utilises validated human antibody drugs, as templates for creating animal-specific versions. Human biologicals are supported by years of clinical success and currently achieve annual sales of greater than $50 billion. Nexvet is actively developing a pipeline of PETised™ antibody drugs to create a major market opportunity in veterinary medicine, with a number of studies completing important clinical studies over the coming months.

Ms Farrell said Nexvet's portfolio of products represented a huge opportunity.

"Nexvet has an incredibly exciting business proposition and an innovative platform technology, which has the potential to vastly improve animal treatments around the globe," she said.

"Joining Nexvet was the logical next step for me and I am delighted to be joining an experienced team in bringing the company's exciting product line through clinical development and exploring commercialisation opportunities."

"As a dog lover myself, joining Nexvet also brings a lot of personal satisfaction. Buddy, our labradoodle, was fully supportive of this unique career opportunity. "

Ms Farrell will take up her position with Nexvet on August 12.